Scilex Holding Co (SCLX)
0.86
+0.01
(+1.37%)
USD |
NASDAQ |
May 03, 16:00
0.8495
-0.01
(-1.22%)
After-Hours: 20:00
Scilex Enterprise Value: 212.81M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 212.81M |
| May 02, 2024 | 211.58M |
| May 01, 2024 | 212.34M |
| April 30, 2024 | 212.09M |
| April 29, 2024 | 219.40M |
| April 26, 2024 | 214.99M |
| April 25, 2024 | 212.90M |
| April 24, 2024 | 211.75M |
| April 23, 2024 | 225.19M |
| April 22, 2024 | 222.51M |
| April 19, 2024 | 216.82M |
| April 18, 2024 | 217.06M |
| April 17, 2024 | 245.71M |
| April 16, 2024 | 244.65M |
| April 15, 2024 | 257.38M |
| April 12, 2024 | 262.69M |
| April 11, 2024 | 259.50M |
| April 10, 2024 | 263.75M |
| April 09, 2024 | 265.87M |
| April 08, 2024 | 269.05M |
| April 05, 2024 | 283.91M |
| April 04, 2024 | 283.91M |
| April 03, 2024 | 284.97M |
| April 02, 2024 | 286.03M |
| April 01, 2024 | 288.16M |
| Date | Value |
|---|---|
| March 28, 2024 | 290.28M |
| March 27, 2024 | 292.40M |
| March 26, 2024 | 281.79M |
| March 25, 2024 | 276.48M |
| March 22, 2024 | 274.36M |
| March 21, 2024 | 270.12M |
| March 20, 2024 | 265.87M |
| March 19, 2024 | 264.81M |
| March 18, 2024 | 266.93M |
| March 15, 2024 | 266.93M |
| March 14, 2024 | 269.05M |
| March 13, 2024 | 262.69M |
| March 12, 2024 | 261.63M |
| March 11, 2024 | 270.12M |
| March 08, 2024 | 272.24M |
| March 07, 2024 | 269.05M |
| March 06, 2024 | 265.87M |
| March 05, 2024 | 260.27M |
| March 04, 2024 | 255.57M |
| March 01, 2024 | 255.07M |
| February 29, 2024 | 348.58M |
| February 28, 2024 | 363.58M |
| February 27, 2024 | 352.58M |
| February 26, 2024 | 328.58M |
| February 23, 2024 | 296.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
211.05M
Minimum
Nov 21 2023
2.163B
Maximum
Apr 12 2023
661.96M
Average
561.80M
Median
Dec 31 2022
Enterprise Value Benchmarks
| Sorrento Therapeutics Inc | -- |
| Adial Pharmaceuticals Inc | 4.066M |
| Precision BioSciences Inc | -21.51M |
| Humacyte Inc | 444.71M |
| Perspective Therapeutics Inc | 1.055B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.40M |
| Revenue (Quarterly) | 13.46M |
| Total Expenses (Quarterly) | 31.80M |
| EPS Diluted (Quarterly) | -0.25 |
| Gross Profit Margin (Quarterly) | 66.42% |
| Profit Margin (Quarterly) | -159.0% |
| Earnings Yield | -150.0% |
| Normalized Earnings Yield | -147.44 |